Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
| Datum | Name des Inhabers | Gehandelte Aktien | Wertspanne ($) | Transaktionstyp | Preisspanne ($) | Aktien am Meldungsende | % Veränderung |
|---|---|---|---|---|---|---|---|
| 2026-05-07 | Mr. Matthew C. BuschCAO & VP of Finance | -41,00 | 13,58k | Sale to Issuer | 331,11 | 3,15k | -1,29% |
| 2026-05-07 | Mr. Esteban SantosExec. VP of Operations | -522,00 | 172,84k | Sale to Issuer | 331,11 | 75,32k | -0,69% |
| 2026-05-07 | Dr. David M. ReeseExec. VP & CTO | -556,00 | 184,10k | Sale to Issuer | 331,11 | 33,24k | -1,64% |
| 2026-05-07 | Mr. Derek MillerSVP of HR | -151,00 | 50,00k | Sale to Issuer | 331,11 | 9,86k | -1,51% |
| 2026-05-07 | Ms. Rachna KhoslaSVP of Business Development | -93,00 | 30,79k | Sale to Issuer | 331,11 | 6,88k | -1,33% |
| 2026-05-07 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -88,00 | 29,14k | Sale to Issuer | 331,11 | 5,96k | -1,46% |
| 2026-05-07 | Mr. Peter H. GriffithExec. VP & CFO | -556,00 | 184,10k | Sale to Issuer | 331,11 | 40,13k | -1,37% |
| 2026-05-07 | Mr. Jonathan P. GrahamExec. VP, General Counsel & Secretary | -499,00 | 165,22k | Sale to Issuer | 331,11 | 31,65k | -1,55% |
| 2026-05-07 | Mr. Murdo GordonEVP of Global Markets & Policy, Medical, Commercial Operations, Government Affairs and Policy | -615,00 | 203,63k | Sale to Issuer | 331,11 | 40,84k | -1,48% |
| 2026-05-07 | Mr. Robert A. BradwayChairman & CEO | -2,08k | 688,38k | Sale to Issuer | 331,11 | 620,48k | -0,33% |
| 2026-05-07 | Dr. James E. BradnerEVP of Research & Development, Artificial Intelligence and Data | -446,00 | 147,68k | Sale to Issuer | 331,11 | 7,10k | -5,91% |
| 2026-05-06 | Dr. James E. BradnerEVP of Research & Development, Artificial Intelligence and Data | -407,00 | 134,14k | Sale to Issuer | 329,59 | 6,60k | -5,81% |
| 2026-05-06 | Mr. Robert A. BradwayChairman & CEO | -1,70k | 560,96k | Sale to Issuer | 329,59 | 618,61k | -0,27% |
| 2026-05-06 | Mr. Matthew C. BuschCAO & VP of Finance | -50,00 | 16,48k | Sale to Issuer | 329,59 | 3,08k | -1,60% |
| 2026-05-06 | Mr. Murdo GordonEVP of Global Markets & Policy, Medical, Commercial Operations, Government Affairs and Policy | -502,00 | 165,45k | Sale to Issuer | 329,59 | 40,29k | -1,23% |
| 2026-05-06 | Mr. Jonathan P. GrahamExec. VP, General Counsel & Secretary | -408,00 | 134,47k | Sale to Issuer | 329,59 | 31,20k | -1,29% |
| 2026-05-06 | Mr. Peter H. GriffithExec. VP & CFO | -502,00 | 165,45k | Sale to Issuer | 329,59 | 39,63k | -1,25% |
| 2026-05-06 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -76,00 | 25,05k | Sale to Issuer | 329,59 | 5,88k | -1,28% |
| 2026-05-06 | Ms. Rachna KhoslaSVP of Business Development | -79,00 | 26,04k | Sale to Issuer | 329,59 | 6,80k | -1,15% |
| 2026-05-06 | Mr. Derek MillerSVP of HR | -123,00 | 40,54k | Sale to Issuer | 329,59 | 9,72k | -1,25% |
| 2026-05-06 | Dr. David M. ReeseExec. VP & CTO | -454,00 | 149,63k | Sale to Issuer | 329,59 | 32,75k | -1,37% |
| 2026-05-06 | Mr. Esteban SantosExec. VP of Operations | -427,00 | 140,73k | Sale to Issuer | 329,59 | 74,85k | -0,57% |
| 2026-05-02 | Mr. Esteban SantosExec. VP of Operations | -1,34k | 441,30k | Sale to Issuer | 329,82 | 74,44k | -1,77% |
| 2026-05-02 | Dr. David M. ReeseExec. VP & CTO | -1,43k | 472,63k | Sale to Issuer | 329,82 | 32,31k | -4,25% |
| 2026-05-02 | Mr. Derek MillerSVP of HR | -365,00 | 120,38k | Sale to Issuer | 329,82 | 9,61k | -3,66% |
| 2026-05-02 | Ms. Rachna KhoslaSVP of Business Development | -225,00 | 74,21k | Sale to Issuer | 329,82 | 6,72k | -3,24% |
| 2026-05-04 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -1,24k | 400,45k | Verkauf | 323,73 | 5,81k | -17,56% |
| 2026-05-02 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -242,00 | 79,82k | Sale to Issuer | 329,82 | 5,81k | -4,00% |
| 2026-05-02 | Mr. Peter H. GriffithExec. VP & CFO | -1,43k | 472,63k | Sale to Issuer | 329,82 | 39,16k | -3,53% |
| 2026-05-02 | Mr. Jonathan P. GrahamExec. VP, General Counsel & Secretary | -1,26k | 414,58k | Sale to Issuer | 329,82 | 30,81k | -3,92% |
| 2026-05-02 | Mr. Murdo GordonEVP of Global Markets & Policy, Medical, Commercial Operations, Government Affairs and Policy | -1,59k | 525,40k | Sale to Issuer | 329,82 | 39,81k | -3,85% |
| 2026-05-02 | Mr. Matthew C. BuschCAO & VP of Finance | -68,00 | 22,43k | Sale to Issuer | 329,82 | 2,99k | -2,22% |
| 2026-05-02 | Mr. Robert A. BradwayChairman & CEO | -5,06k | 1,67M | Sale to Issuer | 329,82 | 616,98k | -0,81% |
| 2026-03-16 | Mr. Esteban SantosExec. VP of Operations | -5,62k | 2,06M | Sale to Issuer | 366,21 | 73,37k | -7,12% |
| 2026-03-16 | Dr. David M. ReeseExec. VP & CTO | -6,02k | 2,21M | Sale to Issuer | 366,21 | 31,16k | -16,20% |
| 2026-03-16 | Mr. Derek MillerSVP of HR | -1,62k | 591,80k | Sale to Issuer | 366,21 | 9,31k | -14,78% |
| 2026-03-16 | Ms. Rachna KhoslaSVP of Business Development | -707,00 | 258,91k | Sale to Issuer | 366,21 | 6,54k | -9,75% |
| 2026-03-16 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -787,00 | 288,21k | Sale to Issuer | 366,21 | 6,86k | -10,29% |
| 2026-03-16 | Mr. Peter H. GriffithExec. VP & CFO | -5,75k | 2,10M | Sale to Issuer | 366,21 | 38,01k | -13,14% |
| 2026-03-16 | Mr. Jonathan P. GrahamExec. VP, General Counsel & Secretary | -5,35k | 1,96M | Sale to Issuer | 366,21 | 29,80k | -15,23% |
| 2026-03-16 | Mr. Murdo GordonEVP of Global Markets & Policy, Medical, Commercial Operations, Government Affairs and Policy | -6,69k | 2,45M | Sale to Issuer | 366,21 | 38,53k | -14,80% |
| 2026-03-16 | Mr. Robert A. BradwayChairman & CEO | -21,29k | 7,80M | Sale to Issuer | 366,21 | 612,90k | -3,36% |
| 2026-03-16 | Mr. Matthew C. BuschCAO & VP of Finance | -327,00 | 119,75k | Sale to Issuer | 366,21 | 2,89k | -10,17% |
| 2026-03-04 | Mr. Robert A. BradwayChairman & CEO | 35,50k | 5,55M | Derivative Exercise and Retained Stock | 156,35 | 633,62k | 5,93% |
| 2026-03-04 | Mr. Robert A. BradwayChairman & CEO | -84,29k | 18,79M | Derivative Exercise and Sale | 156,35 - 379,27 | 633,62k | - |
| 2026-02-26 | Mr. Esteban SantosExec. VP of Operations | -54,79k | 11,50M | Derivative Exercise and Sale | 162,60 - 379,12 | 68,16k | - |
| 2026-02-19 | Mr. Matthew C. BuschCAO & VP of Finance | -1.000,00 | 375,79k | Verkauf | 375,79 | 2,26k | -30,64% |
| 2026-02-09 | Dr. James E. BradnerEVP of Research & Development, Artificial Intelligence and Data | -3,10k | 1,19M | Sale to Issuer | 384,32 | 15,21k | -16,95% |
| 2025-11-20 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -3,14k | 525,98k | Derivative Exercise and Sale | 162,60 - 337,26 | 5,59k | - |
| 2025-11-12 | Ms. Rachna KhoslaSVP of Business Development | -890,00 | 299,26k | Verkauf | 336,24 | 5,04k | -15,02% |
| 2025-11-12 | Mr. Murdo GordonEVP of Global Markets & Policy, Medical, Commercial Operations, Government Affairs and Policy | -6,88k | 2,32M | Verkauf | 336,83 | 29,52k | -18,90% |
| 2025-11-11 | Dr. David M. ReeseExec. VP & CTO | -6,80k | 0,00 | Other Disposition | - | 23,90k | -22,15% |
| 2025-11-05 | Ms. Rachna KhoslaSVP of Business Development | -226,00 | 67,05k | Sale to Issuer | 296,70 | 6,02k | -3,62% |
| 2025-11-05 | Mr. Matthew C. BuschCAO & VP of Finance | -202,00 | 59,93k | Sale to Issuer | 296,70 | 3,11k | -6,10% |
| 2025-08-20 | Ms. Nancy A. GrygielSenior VP of Worldwide Compliance & Business Ethics and CCO | -1,27k | 376,28k | Verkauf | 296,99 | 5,58k | -18,51% |
| 2025-06-05 | Ms. Rachna KhoslaSVP of Business Development | -1,50k | 434,52k | Verkauf | 289,68 | 5,91k | -20,25% |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Mit E-Mail registrieren
Haben Sie schon ein Konto? Anmelden
Haben Sie kein Konto? Registrieren
Durch die Registrierung bestätige ich, dass ich die Allgemeinen Geschäftsbedingungen von ADVFN gelesen und verstanden habe und ihnen zustimme und dass ich ein Privatinvestor bin.
Premium
